Xencor (XNCR) Research & Development (2013 - 2026)
Xencor (XNCR) reported Research & Development of $64.7 million for Q1 2026, up 10.4% year-over-year from $58.6 million in Q1 2025, and little changed quarter-over-quarter from $64.8 million in Q4 2025.
Xencor (XNCR) Research & Development (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Research & Development data on file, last reported at $64.7 million in Q1 2026.
- Research & Development for Q1 2026 came in at $64.7 million, up 10.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $245.5 million (up 7.03% YoY), and the FY2025 annual result was $239.4 million, up 5.16% from the prior year.
- Research & Development steadied at $64.7 million in Q1 2026 per XNCR's latest filing, from $64.8 million in the prior quarter.
- Over five years, Research & Development peaked at $64.9 million in Q3 2023 and troughed at $47.1 million in Q2 2022.
- A 5-year average of $57.9 million and a median of $58.6 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development jumped 34.81% in 2023, then dropped 20.5% in 2024.
- A 5-year view of Research & Development shows it stood at $51.5 million in 2022, then rose by 24.82% to $64.2 million in 2023, then declined by 20.5% to $51.1 million in 2024, then advanced by 26.97% to $64.8 million in 2025, then retreated by 0.24% to $64.7 million in 2026.
- Business Quant data shows XNCR's Research & Development at $64.7 million in Q1 2026, $64.8 million in Q4 2025, and $54.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 64.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.67 Mn |
| Dec 31, 2025 | 64.82 Mn |
| Sep 30, 2025 | 54.37 Mn |
| Jun 30, 2025 | 61.67 Mn |
| Mar 31, 2025 | 58.58 Mn |
| Dec 31, 2024 | 51.06 Mn |
| Sep 30, 2024 | 58.23 Mn |
| Jun 30, 2024 | 61.53 Mn |
| Mar 31, 2024 | 56.87 Mn |
| Dec 31, 2023 | 64.22 Mn |
| Sep 30, 2023 | 64.94 Mn |
| Jun 30, 2023 | 60.06 Mn |
| Mar 31, 2023 | 64.38 Mn |
| Dec 31, 2022 | 51.45 Mn |
| Sep 30, 2022 | 53.27 Mn |
| Jun 30, 2022 | 47.08 Mn |
| Mar 31, 2022 | 47.76 Mn |
| Dec 31, 2021 | 50.99 Mn |
| Sep 30, 2021 | 50.61 Mn |
| Jun 30, 2021 | 49.50 Mn |